Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

18
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
18
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

17
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
17
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.8K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.6K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline Pathogenic Variant Prediction Model for Tumor-Only Sequencing Based on Japanese Clinicogenomic Database.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

More subtle microsatellite instability better predicts fluorouracil insensitivity in colorectal cancer patients.

Scientific reports·2024
Same author

Mutation spectra of the BRCA1/2 genes in human breast and ovarian cancer and germline.

Environmental and molecular mutagenesis·2024
Same author

Serum/glucocorticoid-regulated kinase 1 contributes to the proliferation of varicella-zoster virus and induction of cyclin B1 expression.

Archives of virology·2024
Same author

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.

JTO clinical and research reports·2024
Same author

Early chest tube removal regardless of drainage volume after anatomic pulmonary resection: A multicenter, randomized, controlled trial.

The Journal of thoracic and cardiovascular surgery·2024

Related Experiment Video

Updated: Feb 16, 2026

Application of Design Aspects in Uniaxial Loading Machine Development
05:23

Application of Design Aspects in Uniaxial Loading Machine Development

Published on: September 19, 2018

6.4K

Methodological aspects of current problems in target-based anticancer drug development.

Takeharu Yamanaka1, Tatsuro Okamoto, Yukito Ichinose

  • 1Cancer Statistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan.

International Journal of Clinical Oncology
|July 20, 2006
PubMed
Summary
This summary is machine-generated.

Target-based cancer drugs face challenges due to molecular complexity and limited understanding. Identifying specific tumor-promoting molecular changes is crucial for developing effective anticancer therapies and patient selection.

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K
Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.9K

Related Experiment Videos

Last Updated: Feb 16, 2026

Application of Design Aspects in Uniaxial Loading Machine Development
05:23

Application of Design Aspects in Uniaxial Loading Machine Development

Published on: September 19, 2018

6.4K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K
Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Conventional antineoplastic agents differ from target-based drugs, which are designed using molecular biology insights.
  • Target-based drug development, while revolutionary, faces limitations due to incomplete knowledge of molecular functions and target dispersion caused by structural similarities.

Purpose of the Study:

  • To address the challenges in target-based drug development, including unexpected adverse effects and low response rates.
  • To highlight the need for precise identification of molecular changes driving tumor growth and predicting drug response.

Main Methods:

  • The study critically analyzes the limitations of current molecular biology approaches, such as elementalism.
  • It discusses the difficulties encountered in drug design, clinical trials, and patient administration due to target dispersion.

Main Results:

  • Many target-based drugs are abandoned due to unforeseen adverse effects and lower-than-expected efficacy.
  • The 'out-of-focusing' issue in drug development stems from methodological limits in molecular biology and drug development techniques.

Conclusions:

  • Overcoming current limitations requires elucidating specific molecular changes that promote tumor growth.
  • Precise and efficient detection of patient populations likely to respond is key to establishing successful target-based anticancer therapies.